



*News Release*

**NeurAxon, Inc. to Present at 26th Annual JPMorgan Healthcare Conference January 10, 2008**

**WALTHAM, MA. January 4, 2008 --** NeurAxon, Inc. is pleased to announce that Lawrence Bloch, M.D., J.D., the Company's Chief Executive Officer will present at the 26th Annual JPMorgan Healthcare Conference to be held January 7-10, 2008 in San Francisco, California.

The NeurAxon presentation will begin at 10:00 am Pacific Time on Thursday, January 10, 2008 in the Elizabethan CD room at the Westin St. Francis Hotel.

Dr. Bloch will provide an overview of NeurAxon and its portfolio of novel pain therapeutics including its lead candidate, NXN-188, an oral, first-in-class, selective nNOS inhibitor and 5HT antagonist which is entering Phase 2 trials for acute migraine.

**About NeurAxon Inc.**

NeurAxon Inc. ([www.neuraxon.com](http://www.neuraxon.com)) is a leader in discovering and developing next generation pain therapeutics targeting neuronal nitric oxide synthase (nNOS), an enzyme involved in modulating pain and central nervous system neuronal sensitization.

**Contact:**

Chris Erdman  
MacDougall Biomedical Communications  
617.686.1718